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Non-alcoholic fatty liver disease (NAFLD) affects one in every
three subjects in the occidental world. The vast majority will
not progress, but a relevant minority will develop liver cirrhosis
and its complications. The classical gold standard for diagnosing
and staging NAFLD and assessing ﬁbrosis is liver biopsy (LB). How-
ever, it has important sample error issues and subjectivity in the
interpretation, apart from a small but real risk of complications.
The decision to perform an LB is even harder in a condition so pre-
valent such as NAFLD, in which the probability of ﬁnding severe
liver injury is low. In an attempt to overcome LB and to subcate-
gorize patients with NAFLD in different prognoses allowing better
management decisions, several non-invasive methods have been
studied in the last decade. The literature is vast and confusing.
This review will summarize which methods have been tested
and how they perform, which tests are adequate for clinical prac-
tice and how they can change the management of these patients.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Non-alcoholic fatty liver disease (NAFLD) is the hepatic pandemic
of the XXI century, being the number one cause of chronic hepatic
disease in the occidental world [1]. Although usually benign, fattyJournal of Hepatology 20
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ARFI, acoustic radiation force impulse.liver may associate with serious injury, with inﬂammation and
hepatocyte necro-apoptosis, non-alcoholic steatohepatitis
(NASH), in 20–30% of subjects [2]. Those patients are at risk of
developing ﬁbrosis, one ﬁfth progressing to liver cirrhosis [2]. It
is apparently more slowly progressive than other chronic liver
diseases, such as alcohol or viral-induced disease [3]. However,
because NAFLD is so common, occurring in one out of three per-
sons in the developed world [1], it is the third cause of liver trans-
plantation in the United States [4]. Moreover, the problem of
hepatocytes being fatty, overcomes the liver itself, as it increases
the risk for cardiovascular disease and death and duplicates the
risk for type 2 diabetes mellitus (T2DM), independently of the
severity of liver injury [5].
The gold standard for the diagnosis and staging of NAFLD is
liver biopsy (LB), although as it will be discussed later, it may
have been dethroned by more accurate methods in what con-
cerns steatosis. However, it is the only way to directly diagnose
NASH and ﬁbrosis, even if several assays and models try to pre-
dict it with reasonably good accuracy. LB has several drawbacks.
It is an invasive procedure, frequently associated with distress
and discomfort. Although generally safe, it comes with a risk
for major complications in 1–3% and even death in 0.01% [6].
The second issue relates to sampling problems, which results in
misdiagnosis in a very signiﬁcant number of cases. In fact, NASH
may be wrongly excluded in up to one fourth of the cases and
ﬁbrosis severity misclassiﬁed in up to one third of the patients
[7]. That propensity for sampling error relates to the procedure
and to the disease. Even an adequate LB will show only
0.05 cm3 from an organ whose volume ranges between 800 and
1000 cm3, corresponding to less than 1:50,000 of the total vol-
ume [6]. Also, in NAFLD, lesions are not evenly distributed [7].
Lastly, diagnosis is dependent on the subjectivity and experience
of the pathologist, mostly in identifying ballooning and grading
necro-inﬂammation.
Several non-invasive methods aim at diagnosing and quanti-
fying hepatic steatosis, while others were designed to predict
NASH or signiﬁcant/advanced ﬁbrosis. In this review, the ratio-
nale for pursuing each diagnosis and instruments available will
be discussed. The reliability and importance of diagnostic tests
depend on the disease, the population where it is applied and
the change in management induced by the test’s result. A good
screening test should have a high sensitivity (Se) even at expense
of speciﬁcity (Sp), whereas a diagnostic test that selects patients
for invasive procedures, therapy or clinical trials should have13 vol. 58 j 1007–1019
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high Sp. The most common approach to evaluate a test has been
the analysis of the Receiving Operating Characteristic (ROC)
curves and the area under ROC (AUROC), which evaluates the
probability of a test discriminating a true positive (Se) against
the probability of ﬁnding a false positive result (1-Sp). When
the AUROC is higher than 0.8, it suggests good accuracy. It is a
valuable tool but must be analysed carefully, particularly when
comparing different tests. Although Se and Sp are invariant for
a diagnostic test, they may depend on the characteristics of the
population, such as age, gender and severity of disease. Thus, it
may not be accurate to compare AUROC of different tests in dif-
ferent studies, with different populations and no statistical work
done comparing them.Identiﬁcation and quantiﬁcation of hepatic steatosis
The ﬁrst challenge is when to suspect NAFLD. Suspicion will not
be driven by clinical manifestations, since most patients are
asymptomatic. Symptomatic patients present unspeciﬁc com-
plaints such as fatigue, abdominal discomfort and, only seldom,
manifestations of advanced liver disease. There are, however,
high-risk populations in whom the prevalence is so high that
per se is enough to raise the hypothesis of NAFLD. In fact, up to
two thirds of patients with obesity and T2DM, present with hepa-
tic steatosis [8]. Also, liver tests, namely aminotransferases, are
usually normal, and when increased, typically present mild eleva-
tion with a ﬂuctuant pattern [9]. Isolated increase in alkaline
phosphatase is not frequent, but it has been reported in 10% of
patients referred to tertiary care [10].
We should ask whether it is worth searching and diagnosing
NAFLD in asymptomatic subjects with normal liver tests, since
the majority will have non-progressive simple steatosis. Then
again, hepatic steatosis is linked to an increase in cardiovascular
risk and death. Particularly in diabetic patients, steatosis
increases by more than 3-fold the risk for overall death [11]
and cardiovascular disease [12]. Even in these high-risk patients,
there is controversy regarding screening, among endocrinolo-
gists. Some do not recommend it, advocating that traditional
scores should assess cardiovascular risk, while others consider
diagnosis and evaluation of NAFLD as part of the management
of DM being an indication for more intense monitoring and ther-
apeutic intervention [13]. The guidelines on NAFLD from the
American Association for the Study of Liver Diseases discourage
screening for hepatic steatosis, even in high-risk patients such
as diabetics. There is not enough evidence regarding diagnostic
tools and treatment options, and there are no studies on the
cost-effectiveness of a screening program [14]. There are how-
ever, situations in which an active search for NAFLD in asymp-
tomatic subjects is warranted: liver donors for liver transplant,
as steatosis is a risk for graft primary non-function, and in major
hepatic resection [15], in which steatosis increases the risk for
post-operative morbi-mortality [16].
The second question, if it is meaningful to quantify steatosis, is
difﬁcult to answer, since it has not been consistently demon-
strated that the amount of fat inﬂuences prognosis. Also, it is
yet to be elucidated if decreasing the amount of hepatic fat with
therapeutic interventions will favourably affect the cardio-meta-
bolic risk and the risk for progression to advanced liver disease.
Several diagnostic panels have been proposed to predict
steatosis (Table 1). Steatotest incorporates 12 variables in an1008 Journal of Hepatology 2013undisclosed formula, including a2-macroglobulin, haptoglobin,
and apolipoprotein A1 [17]. In a French cohort of more than
700 patients, it showed reasonable accuracy, with 0.79 AUROC
for moderate-severe steatosis, good negative predictive value
(NPV), 93%, but small positive predictive value (PPV), 63%.
Another French group found similar results in 288 morbid obese
subjects [18]. The Poynard’ group conducted a meta-analysis in
morbid obese subjects, obtaining the same conclusions [19]. We
have to acknowledge that AUROC was suboptimal, it has been
validated only in French cohorts, it incorporates tests not used
routinely and because the formula is not public, a fee is imposed
for each test applied.
Bedogni et al.ﬁrst proposed Fatty Liver Index (FLI) in 2006, as an
algorithmderived from the population of the Dionysos Nutrition&
Liver Study [20]. The gold standard was ultrasonography (US). The
index varies between 0 and 100 and is calculated through a for-
mula incorporating: body mass index (BMI), waist circumference,
triglycerides and c-glutamyltranspeptidase (GGT). It showed good
accuracy in detecting NAFLD and it has been used in several popu-
lation studies [21,22]. However, the gold standard used is far from
ideal, and as such, the results should be interpreted carefully. Its
main indication is for epidemiological studies, in an attempt to
avoid US. Recently, a study on 2075 middle-aged Caucasians from
the Regional Health Registry, followed for 15 years, showed that
FLI independently associates with overall, cardiovascular and can-
cer-related mortality [23].
The same group also proposed Lipid Accumulation Product
(LAP) that incorporates gender, waist circumference and triglyc-
erides. After log-transformation, for each log unit increment,
the risk for steatosis increased more than 4 folds [24]. Although
this is a very simple test to apply, it needs validation by indepen-
dent groups.
Recently, NAFLD Liver Fat Score [25] derived from a Finnish
population. Gold standard was magnetic resonance spectroscopy
(MRS). The score incorporates simple variables: presence of the
metabolic syndrome and T2DM, fasting serum insulin, aspartate
aminotransferase (AST) and AST/alanine aminotransferase (ALT)
ratio. It yielded 95% Se and Sp. Information on PNPLA3 gene
(rs738409) improved the accuracy for the prediction in less than
1%. A Netherlands’ group conﬁrmed these results [26]. It may be a
test to take into account when assessing steatosis easily on the
bench without recurring to radiology.
The best non-invasive tests for the diagnosis of steatosis are
the imaging ones. US should be the ﬁrst method to be used in a
clinical setting. It is inexpensive, widely available and it has
60–94% Se and 66–97% Sp for hepatic steatosis [27–29]. However,
US acuity decreases dramatically for mild steatosis. In a study on
100 living donors for liver transplant, US could not detect steato-
sis when present in less than 10% of hepatocytes, and detected
only 55% and 72% of patients, with steatosis 10–19% and 20–
29%, respectively [30]. As it is a subjective evaluation, several
attempts have tried to make it quantitative. A hepato-renal index
contrast above 7.0 dB presented 91% Se and 84% Sp for hepatic
steatosis [31]. A semi-quantitative score has been proposed, the
Ultrasonographic Fatty Liver Indicator (US-FLI) [32]. It requires
the presence of liver/kidney contrast (brighter liver than kidney)
among other parameters. A score of at least 2 is highly indicative
of NAFLD. US has several limitations: it is unreliable in the detec-
tion of mild steatosis, it has only up to 67% PPV [33], it is operator
dependent with low inter and intra-observer agreement for stea-
tosis, around 70% and 50% for steatosis presence and severity,vol. 58 j 1007–1019
Table 1. Complex scores for predicting steatosis.
Author, [Ref.] Score’s name N Formula Results Validation
Poynard T et al., 
2005, [17]
Steatotest 310 - training group
434 - 3 validation groups
Undisclosed formula incorporating: α2-MG, haptoglobin, apolipoprotein 
A1, total bilirubin, GGT, fasting glucose, triglycerides, cholesterol, ALT, 
age, gender and BMI
AUROC 0.79 
(steatosis >33%)
2 cut-offs: 0.3 and 0.72 - 
Se 90%, Sp 70%, PPV 
63%, NPV 93%
In other French cohorts 
(total 494 patients) - 
similar results [18, 19]
Bedogni G et al., 
2006, [20]
Fatty Liver Index 
(FLI)
216 patients
280 controls
(e0.953 * Loge(triglycerides) + 0.139 * BMI + 0.718 * Loge(GGT) + 0.053 * (waist circumference)-15.745)/
(1 + e0.953 * Loge(triglycerides) + 0.139 * BMI + 0.718 * Loge(GGT) + 0.053 * (waist circumference)-15.745) * 100
AUROC 0.84 
(steatosis by US)
2 cut-offs, <30 for excluding 
and >60 for ruling - 
Se 87%, 86% Sp
Widely used in 
epidemiological studies
Kotronen A et al., 
2009, [25]
NAFLD Liver Fat 
Score
313 - training group
157 - validation group
-2.89 + 1.18 * (metabolic syndrome - yes = 1/no = 0) + 
0.45 * (type 2 diabetes mellitus - yes = 1/no = 0) + 0.15 * (fasting serum 
insulin, mU/L) + 0.04 * (AST, IU/L) - 0.94 * (AST/ALT)
AUROC 0.87
2 cut-offs, -1.413 and 
+1.257 - 
Se and Sp 95%
A Netherlands’ group 
[26]
Bedogni G et al., 
2010, [24]
Lipid Accumulation 
Product (LAP)
588 subjects (waist circumference - 65) * triglycerides if men and 
(waist circumference - 58) * triglycerides if women
For each log unit increase, 
OR for steatosis 4.28
Ballestri S et al., 
2012, [32]
Ultrasonographic 
Fatty Liver Indicator 
(US-FLI)
53 patients Brighter liver than kidney, whose intensity in contrast can be graded as 
mild/moderate (2 points) or severe (3 points).
One extra point for each of the following:
1. Posterior attenuation of ultrasound beam,
2. Vessel blurring,
5. Areas of focal sparing 
Score ≥2 - highly indicative 
of NAFLD
Score ≥4 - predicts NASH: 
AUROC 0.796, 
NPV 94%, Se 46%
CT scores 1. Liver parenchyma attenuation (CTLP):
2. Liver to spleen attenuation difference (CTL-S):
normal range - 8 to 10 HU
3. Liver to spleen attenuation ratio (CTL/S)
CTLP <40 HU - 
Se 52%, Sp 100% 
CTL-S >10 HU - 
Se 60%, Sp 100% 
CTL/S >1.1 - 
Se 82%, Sp 100% 
Several validations
Zardi EM et al., 
2011, [67]
Zardi’s US score 94 patients 
(retrospective)
Two parameters:
1. Echo amplitude attenuation scored from 0 if absent, 1 mild and 
2 severe,
2. Presence/absence of focal fat sparing 
Score ≥1 could - 
Se 92%, Sp 75%
3. 
4. 
normal range - 50 to 57 Hounsfield Units (HU)
confirmed these results
Difficult visualization of the diaphragm,
Difficult visualization of the gallbladder wall,
a2-MG, alpha-2 macroglobin; GGT, gamma-glutamyltranspeptidase; ALT, alanine aminotransferase; BMI, body mass index; AUROC, area under receiver operating characteristic; Se, sensitivity; Sp, speciﬁcity; PPV, positive
predictive value; NPV, negative predictive value; NAFLD, non-alcoholic fatty liver disease; AST, aspartate aminotransferase; NASH, non-alcoholic steatohepatitis; HU, Hounsﬁeld Units.
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respectively [34]. Its accuracy signiﬁcantly decreases in morbid
obesity, with Se below 50% and 75% Sp in those patients [35].
In addition, graduation of steatosis can be biased by ﬁbrosis,
necrosis, oedema, and extra-hepatic adipose tissue. Recently,
the hepatic/renal ratio and hepatic echo/intensity attenuation
rate have been used to quantify steatosis. Xia et al. [36], standard-
ized those measurements by introducing a tissue-mimicking
phantom for a computer-assisted US program, allowing repro-
ducibility among different US equipments. They found a good
correlation between the quantiﬁcation of hepatic fat by MRS
and by using the following formula: liver fat content
(%) = 62.592  US hepatic/renal ratio + US hepatic attenuation
rate  27.863. This is a promising technique needing further
validation.
Hepatic Doppler has been evaluated for the diagnosis and
grading of steatosis. Hepatic veins characteristically have a tri-
phasic waveform, reﬂecting right atrial and inferior vena cava
pressures [37]. In NAFLD patients, abnormal hepatic vein Dopp-
ler, biphasic or monophasic, is frequent, probably by compression
of the hepatic vein by enlarged hepatocytes [37–39]. Portal
venous ﬂow is classically described as continuous, however, it
is normal to detect feeble pulsatility in rhythm with the cardiac
cycle. NAFLD patients frequently present a decrease in pulsatility
index and mean velocity of the portal vein blood ﬂow [37,40].
Furthermore, a decrease in hepatic artery resistance index has
been consistently reported [39,41]. Those approaches need addi-
tional validation and standardization. Regarding steatosis grad-
ing, studies were not consensual.
Computed tomography (CT) has similar accuracy for NAFLD as
US, being superior only for focal steatosis [42]. Steatosis is best
detected in non-enhanced CT as a decrease in the attenuation
of hepatic parenchyma [43]. There are three measures to deter-
mine hepatic steatosis: liver parenchyma attenuation, liver to
spleen attenuation difference and ratio. They all achieved 100%
Sp, but with low Se [44]. CT has several limitations, making it
clinically unacceptable for screening steatosis: it exposes patients
to radiation, other diffuse liver diseases may lead to misdiagnosis
of steatosis, hepatic iron content increases attenuation, inducing
false negatives for steatosis, and attenuation values are scanner
dependent, not standardized between different manufacturers.
Magnetic resonance imaging (MRI) is superior to US in detect-
ing and quantifying minor fat inﬁltration, being able to detect
down to 3% of steatosis [45]. MRI exploits the difference in reso-
nance frequencies between water and fat proton signals to quan-
tify the signal fat fraction, i.e., liver signal attributable to fat and/
or proton density fat fraction, i.e., fraction of mobile protons in
the liver attributable to fat [33]. There are several MRI techniques
that overcome the scope of this review [33,46]. More recently,
MRS that directly measures proton signals from the acyl groups
in hepatocyte triglyceride stores has shown incredible accuracy
for diagnosing and quantifying steatosis. It obtains volume-selec-
tive MR spectra from liver volumes ranging from 1 to 27 cm3. A
study on 345 patients derived from the Dallas Heart Study cohort
deﬁned as normal up to 5.56% fat fraction, the 95th percentile
[47]. The correlations with biopsy-assessed steatosis, although
high, are not perfect, with AUROC 0.95–0.97, 92–100% Se and
92–97% Sp [48]. The discordances between both techniques can
be the result of limitations in the biopsy. In fact, MRS assesses
a larger liver volume, being less susceptible to sampling errors.
MRS detects the amount of triglycerides in the parenchyma
whereas LB quantiﬁes the number of hepatocytes with fat1010 Journal of Hepatology 2013droplets, so both techniques do not quantify exactly the same
thing. Finally, MRS is highly sensitive in detecting small amounts
of triglycerides that may not be enough to form macrovesicles
susceptible to histological visualization [42]. Taken together,
could MRS be the new gold standard for hepatic steatosis diagno-
sis and quantiﬁcation, overcoming LB? Arguments against it are:
lack of information regarding necro-inﬂammation and ﬁbrosis;
moreover it is expensive and not broadly available. The accuracy
of magnetic resonance-derived methods may decrease with sig-
niﬁcant ﬁbrosis, raising the need for lower cut-offs in that situa-
tion [48].
Controlled attenuation parameter (CAP) is a new method that
measures attenuation in the liver using signals acquired by a
transient elastography probe (FibroScan). It relies on the
assumption that fat affects ultrasound propagation. Results range
from 100 to 400 dB/m [49]. Sasso et al. [50] retrospectively eval-
uated CAP in 115 patients, showing AUROCs 0.91 and 0.95 for ste-
atosis higher than 10% and 33%, respectively, and good accuracy
in grading steatosis. It was not affected by liver ﬁbrosis. Subse-
quent prospective studies reported lower accuracy [51,52]. It
has several advantages, it is non-ionising, easy to perform, results
are operator independent not relying on subjective interpreta-
tion. It is also less susceptible to sample error as compared to
LB since it evaluates 100 times more tissue. Of notice, failure to
obtain measurements increases with increased BMI, and it is
not yet available for the XL probes of FibroScan [49]. CAP per-
formed better than Steatotest, FLI or Hepatic Steatosis Index [51].
In summary, in clinical practice, the best way to assess steato-
sis is US, although its accuracy decreases hugely for mild steato-
sis. In contrast, MRS is highly accurate for even minimal amounts
of steatosis and it may even be more reliable than LB; however,
its costs limit its use routinely, being a valuable tool for research
purposes. Furthermore, FLI uses simple indices and may be very
useful in large-scale epidemiological studies, since it avoids radi-
ology. Also, the NAFLD Liver Fat Score can be easily used in clin-
ical practice to discard steatosis in a speciﬁc group of patients
such as with T2DM, in whom it can lead to changes in
management.
Prediction of NASH
NAFLD has been subdivided into benign simple steatosis and
NASH, the latter progressing to cirrhosis in up to 20% of cases
[53]. Consequently, clinical differentiation has signiﬁcant
prognostic implications. However, since there is no effective
treatment for NASH, and all NAFLD patients should be based on
life-style intervention and metabolic disturbances correction, it
is arguable whether the information of having NASH has an
impact in the management. Nonetheless, those patients need clo-
ser follow-up, and are the ones who should be included in clinical
trials.
Clinical signs and symptoms do not differentiate NASH from
simple steatosis. Obesity, particularly central obesity, increases
the risk for advanced disease. Also, dorsocervical lipohypertrophy
is the anthropometric parameter most strongly associated with
NASH and liver injury severity [54].
The metabolic syndrome has been associated with increased
risk for NASH and ﬁbrosis, among NAFLD patients [55,56], and
can help select for LB [14].
Aminotransferases levels are not reliable in identifying NASH
[9,57], presenting low AUROC, 0.6–0.7 [58–60]. Decreasing thevol. 58 j 1007–1019
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cut-off to 19 IU/L increases Se up to 70%, but at the expense of a
dramatic decrease in Sp [61,62]. In summary, patients with
NAFLD and increased aminotransferases levels are at higher risk
of having NASH, but NASH cannot be excluded in patients with
normal levels [63]. A simple model incorporating AST and the
presence of DM showed great accuracy for NASH [64]. GGT can
be of value. Although its association with NASH is not clear, it
associates with increased mortality. In a large population-based
study with a 7-year follow-up, men with NAFLD and increased
GGT had a two-fold increase in mortality [65]. A simple score,
neutrophil to lymphocyte ratio, was suggested to predict NASH.
For each unit increase in the ratio, the likelihood of having NASH
increased by 70% [66].
Several scores using US, showed only modest accuracy for
NASH, with AUROC below 0.8. The US-FLI score showed a 94%
NPV for excluding NASH [32]. Another score incorporating echo
amplitude attenuation and focal fat sparing [67] could distin-
guish NASH with 92% Se. A more promising parameter is the
spleen longitudinal diameter, which presented 0.920 AUROC for
NASH, 88% Se and 95% Sp for values above 116 mm [68]. The
same rationale has been used in CT scan, in which spleen diame-
ter controlled for body surface area could also predict NASH,
though, with low accuracy [69]. Preliminary studies on contrast
US using a microbubble contrast agent showed promising results
in predicting NASH, correlating with pericellular ﬁbrosis rather
than steatosis [70,71]. For the time being, radiology is not accu-
rate to diagnose NASH, and should be used carefully.
Multiple serum biomarkers have been evaluated for predict-
ing NASH. Cytokines did not prove to be valuable. Adiponectin
showed conﬂicting results in NASH [72–75]. Small studies tested
formulas with adipokines, with AUROC around 0.8 that need val-
idation [76,77]. Also, tumor necrosis factor-alpha (TNF-a) and
interleukin-6 seem to be elevated in patients with NASH and
ﬁbrosis, but there are discrepancies among studies and its diag-
nostic value has not been clariﬁed [73,74,76,78–80]. CC-chemo-
kine ligand-2 (CCL2) is the major cytokine in macrophage
recruitment. Two pilot studies showed increased levels in NAFLD
patients vs. controls and in NASH vs. simple steatosis [81,82].
Acute phase proteins have also failed to consistently prove
diagnostic value. C-reactive protein was evaluated for diagnosing
NASH, namely through high-sensitive kits, in more than 1000
NAFLD patients. Most studies failed to demonstrate accuracy
[82–85]. Pentraxin-3 was studied in 70 NAFLD patients, showing
0.755 AUROC for predicting NASH. With 1.61 ng/ml cut-off, it
accomplished 67% Se and 70% Sp [86].
Oxidative stress has been implicated in NASH pathogenesis,
and an increased hepatic lipid peroxidation is accepted [87].
However, plasma and hepatic levels do not correlate, leading to
conﬂicting results when using oxidative stress markers to predict
NASH.
Keratin 18 (CK18) fragments are a marker of hepatocyte apop-
tosis. It is the only biomarker validated in more than 10 studies
and more than 1000 NAFLD patients [58,88–98]. A recent meta-
analysis showed AUROC 0.82 with 78% Se and 86% Sp [5]. Total
levels of CK18, a marker of necrosis, showed equal accuracy to
identify NASH as CK fragments [89,98]. A two-step approach
measuring CK18 following ﬁbroblast growth factor-21 further
increased the predictive value for NASH [97]. CK18 is the most
consistent single parameter for differentiating steatosis from
NASH.Journal of Hepatology 2013Individual groups have suggested multiple biomarkers that
warrant external validation, not being ready to use in clinical
practice. A Turkish study on 71 NAFLD patients, showed that
homocysteine levels can predict NASH with AUROC 0.948; using
a cut-off of 11.935 ng/ml, 92% Se and 96% Sp were achieved [99].
A study on 54 NAFLD patients suggested that serum prolidase
enzyme activity (SPEA) can distinguish NASH from simple steato-
sis with 0.85 AUROC. This enzyme catalyses the ﬁnal step of col-
lagen breakdown [61]. The soluble receptor for advanced
glycation end products (sRAGE) has been implicated in inﬂamma-
tory response, insulin resistance and the metabolic syndrome
[63]. In a pilot study on 57 NAFLD patients, SRAGE showed a
0.77 AUROC for predicting NASH [100].
Several complex models have been created to predict NASH
(Table 2). The majority of them have not been externally vali-
dated and were obtained from speciﬁc populations, most fre-
quently morbid obesity, and thus extrapolation for the whole
NAFLD population is speculative. Dixon et al. [101] created a
score with simple variables: HAIR – Hypertension, increased
ALT and Insulin Resistance, that predicted NASH with great accu-
racy. However, external validation has not been done, and the
study was performed in morbid obese patients.
Palekar et al. [102] predicted NASH by the combination of age,
gender, obesity, hyaluronic acid, AST and AST/ALT ratio. It yielded
only modest Se and Sp. Also, this study included only few
patients and once again was not validated.
Poynard et al. proposed the NashTest [103], an undisclosed
formula incorporating 13 parameters, which presented 94% Sp
but only 33% Se. The authors advise that NashTest should only
be done when SteatoTest is positive. The same considerations
for Steatotest can be made for NashTest.
NASH Diagnostics™ [91] includes, in an undisclosed formula,
cleaved and total CK18, adiponectin and resistin. It derived from
morbid obese patients and showed AUROC 0.854. A re-evaluation
of the score showed lower accuracy [104]. The authors proposed
a different model, NASH Diagnostic Panel, which included DM,
gender, BMI, triglycerides, cleaved and total CK18. This improved
score accomplished a 0.81 AUROC, with good Se and Sp. Once
again, it derives from a small cohort of obese patients, and has
not been externally validated.
The ‘‘Nice model’’ incorporates CK18 fragments, ALT and the
presence of metabolic syndrome [105]. In a large study with
obese patients, it showed good NPV but low PPV. It is also not
known if it adds value to CK18 determination alone.
The Apoptosis Panel [96] includes CK18 fragments, soluble Fas
and Fas ligand, and showed good accuracy in predicting NASH in
a training group, which was not reproducible in a validation
group of morbid obese.
Respiratory tests have also been evaluated for NASH predic-
tion. C-caffeine breath test is a non-invasive quantitative test of
liver function. Caffeine has high oral bioavailability and its
metabolism is almost exclusively done by cytochrome P4501A2.
It showed good accuracy for NASH and signiﬁcant ﬁbrosis
[106,107]. Others found an increase in C-methacin demethylation
(marker of microsomal liver function), decrease in ketoisocapro-
ate decarboxylation and methionine transmethylation (markers
of mitochondrial liver function) [108,109].
Finally, two methods using liver scintigraphy with 99mTc-phy-
tate and 99mTc-HIBI seem promising in detecting NASH. The ﬁrst
showed a decrease in liver/spleen uptake indicative of decreasedvol. 58 j 1007–1019 1011
Table 2. Complex scores for predicting NASH.
Author, [Ref.] Score’s name N Formula Results Validation
Dixon JB et al., 
2001, [101]
HAIR 105 morbid obese 1. Hypertension,
2. Increased ALT (>40 IU/L), 
3. Insulin Resistance (index >5)
≥2 parameters:
AUROC 0.90 
Se 80%, Sp 89%,
Palekar NA et al., 
2006, [102]
Palekar’s Score 80 NAFLD patients Score calculated by the sum of 6 risk factors:
1. Age ≥50 yr,
2. Female sex,
3. Elevated AST (≥45 IU/L),
4. BMI ≥30 kg/m2,
5. AST/ALT ratio ≥0.8, 
6. Plasma levels of hyaluronic acid ≥55 µg/L
≥3 factors:
AUROC of 0.763
Se 74%, Sp 66%, PPV 
68%, NPV 71% 
Poynard T et al., 
2006, [103]
NASH Test 160 - training group
97 - validation group
383 - controls 
Undisclosed formula incorporating: α2-MG, haptoglobin, apolipopro-
tein A1, total bilirubin, GGT, ALT, AST, triglycerides, cholesterol, age, 
gender, height, weight
AUROC 0.79
Se 33%, Sp 94%, PPV 
66%, NPV 81%
In other French cohorts 
(total 494 patients) - 
similar results
Gholam PM et al., 
2007, [64]
Gholam’s model 97 patients -2.627 * lnAST + 2.13 if diabetes mellitus AUROC 0.90
cut-off 6.6 - 
Se 83%, Sp 82%
Younossi ZM et 
al., 2008, [91]
NASH Diagnostics Morbid obese
69 - training group
32 - validation group
Undisclosed formula incorporating: cleaved and total CK18 (M30 and 
M65 antigens, respectively), adiponectin, resistin
combined AUROC 0.90
cut-off 0.432 - 
Se 72%, Sp 91%
The same group 
re-evaluated in 79 
patients: 
AUROC 0.70 [104]
Younossi ZM et 
al., 2011, [104]
NASH Diagnostic 
Panel
79 patients Undisclosed formula incorporating: diabetes mellitus, sex, BMI, 
triglycerides, M30 and M53 antigens
AUROC 0.81
2 cut-offs, 0.221 and 0.6183 
- Se 91%, Sp 92%, 
PPV 83%, NPV 86%
Tamimi TI et al., 
2011, [96]
Apoptosis Panel 95 - training group
82 - validation group 
(morbid obese)
Includes: CK18 fragments, soluble Fas and Fas ligand AUROC 0.93
Cut-off -0.5509 - 
Se 88%, Sp 89%, 
PPV 86%, NPV 91%
Anty R et al., 
2010, [105]
Nice model 464 morbid obese 
patients
Model = -5.654 + 3.780e-02 * ALT (IU/L) + 2.215e-03 * CK 18 fragments 
(IU/L) + 1.825 * (metabolic syndrome: yes = 1, no = 0)
Logarithmic transformation = 1/[1 + Exp(-Nice Model)]
AUROC 0.83-0.88
Cut-off 0.14 - 
Se 84%, Sp 86%, 
PPV 44%, NPV 98% 
NASH, non-alcoholic steatohepatitis; ALT, alanine aminotransferase; AUROC, area under receiver operating characteristic; Se, sensitivity; Sp, speciﬁcity; NAFLD, non-alcoholic fatty liver disease; AST, aspartate amino-
transferase; BMI, body mass index; PPV, positive predictive value; NPV, negative predictive value; a2-MG, alpha-2 macroglobin; GGT, gamma-glutamyltranspeptidase; CK18, cytokeratin 18.
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phagocytosis by Kupffer cells [110]. The latter showed a decrease
in liver/heart ratio, reﬂecting mitochondrial dysfunction [111].
In summary, the most validated tool to predict NASH is the
determination of CK18 fragments. Unfortunately, it is not widely
available in clinical practice. Several complex scores have been
tried, but lack external validation and the majority were only
tested in morbid obese populations.Prediction of signiﬁcant or advanced ﬁbrosis
Facing a particular patient, the presence and severity of ﬁbrosis
are probably the most informative factors regarding prognosis.
Also, recognizing cirrhosis allows the inclusion in screening pro-
tocols for hepatocellular carcinoma and portal hypertension. Sig-
niﬁcant ﬁbrosis has been considered when at least F2 and
advanced when F3 or F4 (Brunt’s classiﬁcation).
Serum tests
Aminotransferases levels are not helpful in identifying ﬁbrosis,
since they can in fact decrease with histological improvement
of steatosis and inﬂammation, despite ﬁbrosis progression
[112]. Also, the whole spectrum of liver disease, including cirrho-
sis, can be found in patients with normal aminotransferases [57].
The AST/ALT ratio can be of more value. In fact, several studies
have found that a ratio above 1 is predictive of advanced ﬁbrosis
[2,113], probably due to an impaired AST clearance by sinusoidal
liver cells. Regarding GGT, a small study suggested modest ability
to predict advanced ﬁbrosis, with a cut-off of 96.6 IU/L presenting
83% Se and 69% Sp [114].
Extracellular matrix components are obvious candidates for
the evaluation of ﬁbrosis. Hyaluronic acid (HA) production is
increased when collagen synthesis is accelerated and, in
advanced liver disease, sinusoidal endothelial dysfunction
decreases its clearance. Small studies have shown it to predict
advanced ﬁbrosis with AUROC 0.75–0.97. Different cut-offs were
used among studies [102,115–117], making it difﬁcult to pool the
data. Type IV collagen 7S domain has also been studied in small
cohorts with similar results as HA [116,118].
Pentraxin-3 showed an AUROC of 0.850 for advanced ﬁbrosis.
A 2.45 ng/ml cut-off accomplished 71% Se, 94% Sp, PPV 81% and
NPV 91% [86]. It is a small study that requires external validation.
Scores
Several models attempt predicting ﬁbrosis, with reasonable accu-
racies for advanced ﬁbrosis, but not for mild/intermediate stages
(Table 3).
Ratziu et al. proposed a simple score, BAAT incorporating age,
BMI, triglycerides and ALT [119]. Although not sensitive, it
yielded 100% Sp.
The European Liver Fibrosis Study group proposed a score, ELF,
after evaluation of more than 1000 patients, including 61 with
NAFLD. It combines age, HA, amino-terminal propeptide of type
III collagen and tissue inhibitor of metalloproteinases (TIMP-1),
and showed excellent AUROC for advanced ﬁbrosis in NASH,
0.87. However, it performed poorly in early and intermediateJournal of Hepatology 2013stages [120]. A simpliﬁed score without age, in 196 patients
showed an even better AUROC, 0.9 [121]. Although this score
has been shown very valuable in ﬁbrosis assessment in large pop-
ulations of viral hepatitis, the NAFLD cohort is still very small to be
used with conﬁdence in this ﬁeld.
FibroTest [122] is an undisclosed formula incorporating: age,
a2-macroglobulin, bilirubin, GGT, and apolipoprotein A1. It was
ﬁrst developed for viral hepatitis and afterwards extended to
NAFLD, where it has shown AUROC for signiﬁcant ﬁbrosis 0.75–
0.86, with excellent Sp. This score was unable to distinguish mild
from moderate ﬁbrosis and one third of the patients were attrib-
uted intermediated values and therefore could not be classiﬁed.
Additional causes of failure were Gilbert syndrome, cholestasis,
acute inﬂammation and abnormal lipoprotein A1 related to lipid
abnormalities frequent in these patients.
NAFLD Fibrosis Score is the most studied score [123], with
external validation in 13 studies, including more than 3000
patients [5]. It incorporates age, glycemia, BMI, platelet count,
albumin, and AST/ALT ratio and presents great accuracy for
advanced ﬁbrosis. A meta-analysis conﬁrmed those results [5].
This score can already be applied in clinical practice, with the
drawback that it will not be useful for one fourth of the patients
that fall in indeterminate values [123].
BARD includes BMI, AST/ALT ratio and presence of DM [124].
In a large convenience sample of NAFLD obese patients, the pres-
ence of at least 2 factors increased 17-fold the risk for advanced
ﬁbrosis, with high NPV. Subsequent studies showed lower accu-
racy, performing worse than NAFLD Fibrosis Score [125–127].
However, it has the advantage of being easier to estimate and
without indeterminate results.
FIB-4, described to evaluate advanced ﬁbrosis in chronic liver
disease, incorporating age, aminotransferases and platelet count,
was compared with several other scores in NAFLD, showing
AUROC most often above 0.80 and always performing the best,
even when compared with NAFLD Fibrosis Score and FibroTest
[127,128]. It is a promising test, maybe using in combination
with other scores.
Fibrometer, which includes glucose, platelet count, amino-
transferases, ferritin, body weight and age, performed better than
NAFLD Fibrosis Score for signiﬁcant ﬁbrosis [129]. It needs exter-
nal validation.
The NAFLD Diagnostic Panel [104] is a score for advanced
ﬁbrosis that includes DM, triglycerides, TIMP-1 and AST. In a
small study, it performed better than ELF, NAFLD Fibrosis Score
and APRI. Those ﬁndings need to be reproduced by other groups
and in larger studies.Measurement of liver stiffness
Transient elastography (FibroScan) evaluates liver stiffness
using pulse-echo ultrasound. It has demonstrated great value in
assessing ﬁbrosis in chronic hepatitis C, and it might also be use-
ful in NAFLD patients, although with less accuracy [130]. The ﬁrst
report in NAFLD was in 67 Japanese patients [131], describing a
stepwise increase in liver stiffness with increase severity of liver
ﬁbrosis, AUROC 0.876, 0.914, and 0.997 for signiﬁcant, advanced
ﬁbrosis and cirrhosis, respectively. An NPV of 100% for excluding
cirrhosis was shown. The ﬁrst larger study on FibroScan invol. 58 j 1007–1019 1013
Table 3. Complex scores for predicting ﬁbrosis.
Author, [Ref.] Score’s name N Formula Results Validation
Ratziu V et al., 
2000, [119]
BAAT 93 NAFLD patients Score calculated by the sum of 4 risk factors:
1. Age ≥50 yr,
2. BMI ≥28 kg/m2,
3. Triglycerides ≥1.7 mmol/L,
4. ALT ≥2 times upper normal limit
AUROC 0.86
The 4 parameters: 
Se 14%, Sp 100%, PPV 
100%, NPV 73%
Gholam PM et al., 
2007, [64]
Gholam’s model 97 patients 2.45 * lnALT - 38.55 (1/HbA1c) + 5 AUROC 0.822
cut-off 6.6 - 
Se 76%, Sp 66%
Rosenberg W et 
al., 2004, [120]
Original European 
Liver Fibrosis score 
(OELF)
1021 patients, 
61 with NAFLD
OELF = -6.38 - (Ln(age) * 0.14) - [Ln(hyaluronic acid) * 0.616] - 
[Ln(amino-terminal propeptide of type III collagen) * 0.586] - [Ln(TIMP-1) 
* 0.472]
AUROC 0.87 for advanced 
cut-off 0.375 - 
Se 89%, Sp 96%, 
PPV 80%, NPV 90%
Guha IN et al., 
2008, [121]
196 NAFLD patients ELF = -7.412 - [Ln(hyaluronic acid) * 0.681] - [Ln(amino-terminal pro-
peptide of type III collagen) * 0.755] - [Ln(TIMP-1) * 0.494]
AUROC 0.87 for advanced 
cut-off -2.3824 - 
Se 91%, Sp 59%, 
PPV 42%, NPV 95%
Ratziu V et al., 
2006, [122]
FibroTest 170 - training group
97 - validation group
Undisclosed formula incorporating: age, α2-macroglobulin, total bilirubin, 
GGT and apolipoprotein A1
AUROC 0.75-0.86 for 
2 cut-off: 0.3 and 0.7 - 
Se 77%, Sp 98%, 
PPV 90%, NPV 73%
Studied by several 
groups in comparison 
with other scores.
Angulo P et al., 
2007, [123]
NAFLD Fibrosis 
Score
480 - training group
253 - validation group
-1.675 + 0.037 * age (yr) + 0.094 * BMI (kg/m2) + 1.13 x IFG/diabetes 
mellitus (yes = 1, no = 0) + 0.99 * AST/ALT ratio - 0.013 * platelet (* 
109/L) - 0.66 x albumin (g/dl)
AUROC 0.84 for advanced 
2 cut-off: -1.455 and 0.676 
- Se 82%, Sp 98%, PPV 
90%, NPV 93%
External validation in 13 
studies, with more than 
3000 patients. The most 
accurate in comparison 
studies.
Harrison SA et 
al., 2008, [124]
BARD 827 NAFLD patients Includes 3 variables:
1. BMI ≥28 kg/m2 (1 point),
2. AST/ALT ratio ≥0.8 (2 points),
3. Diabetes mellitus (1 point)
AUROC 0.81 for advanced 
Score 2-4 - PPV 43%, 
NPV 96%
Studied by several 
groups in comparison 
with other scores.
Calès P et al., 
2009, [129]
Fibrometer 235 NAFLD patients 0.4184 glucose (mmol/L) + 0.0701 AST (IU/L) + 0.0008 ferritin (mg/L) 
- 0.0102 platelet (G/L) - 0.0260 ALT (IU/L) + 0.0459 body weight (kg) + 
0.0842 age (yr) + 11.6226
-
2 cut-off: 0.611 and 0.715 - 
Se 79%, Sp 96%, 
PPV 88%, NPV 92%
McPherson S et 
al., 2010, [127]
FIB-4 145 NAFLD patients age (yr) * AST (IU/L)/platelet count (109/L) * ALT1/2 (IU/L) AUROC 0.86 for advanced 
cut-off: 1.3 - 
Se 85%, Sp 65%, NPV 95%
Younossi ZM et 
al., 2011, [104]
NAFLD Diagnostic 
Panel
79 NAFLD patients Undisclosed formula incorporating: diabetes mellitus, triglycerides, 
TIMP-1 and AST
AUROC 0.81 for advanced 
2 cut-off: 0.0816 and 0.364 
- Se 93%, Sp 91%, PPV 
58%, NPV 95%
Simplified ELF
fibrosis, in NASH
fibrosis, in NASH
significant fibrosis
fibrosis
fibrosis
AUROC 0.943 for signifi
cant fibrosis
fibrosis
fibrosis
NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; ALT, alanine aminotransferase; AUROC, area under receiver operating characteristic; Se, sensitivity; Sp, speciﬁcity; PPV, positive predictive value; NPV,
negative predictive value; TIMP-1, tissue inhibitor of metalloproteinases; NASH, non-alcoholic steatohepatitis; GGT, gamma-glutamyltranspeptidase; IFG, increased fasting glucose; AST, aspartate aminotransferase.
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Low probability for 
(<-1.455)
Intermediate probability for 
(-1.455 to 0.676)
FibroScan®
(-) for NASH
Follow-up
(+) for NASH
Liver biopsy
Liver biopsy
CK18 fragments
Liver biopsy
unless clinical evidence of 
cirrhosis
High probability for 
(>0.676)
NAFLD Fibrosis Score
advanced fibrosis advanced fibrosis advanced fibrosis
(-) for advanced fibrosis (+) for advanced fibrosis
Fig. 1. Algorithm for decision: when to perform liver biopsy. The most validated methods are used in this algorithm, namely NAFLD Fibrosis Score and FibroScan for the
evaluation of ﬁbrosis and CK18 fragments for the evaluation of NASH. The most signiﬁcant prognostic factor is the ﬁbrosis severity, hence is the ﬁrst one to be screened. If
there is clinical evidence of liver cirrhosis, and there is no doubt in terms of the aetiology of liver disease, no further assessment is needed. If NAFLD Fibrosis Score suggests
advanced ﬁbrosis, more than 90% of the patients will have advanced ﬁbrosis, and it is essential to exclude cirrhosis, which would tremendously change the management,
and we would recommend a liver biopsy. If, on the other hand, the NAFLD Fibrosis Score suggests low probability for advanced ﬁbrosis, this can be excluded with a high
conﬁdence since it presents a 93% NPV. It could still be important to exclude the presence of NASH for prognosis purposes. If CK18 is available and it does not suggest NASH,
we could be conﬁdent and maintain the patient in follow-up. On the other hand, if it suggests NASH, it should be conﬁrmed by liver biopsy, since it will be a false positive in
14% of the patients. In the patients unclassiﬁed for NAFLD Fibrosis Score, FibroScan can be useful, with the need to conﬁrm cirrhosis with liver biopsy if it suggests
advanced ﬁbrosis.
JOURNAL OF HEPATOLOGYNAFLD gathered 246 patients from two ethnic groups, a French
and Chinese cohort, showing similar accuracy [132]. The best
cut-offs were 7.0 kPa, 8.7 kPa and 10.3 kPa for signiﬁcant,
advanced ﬁbrosis and cirrhosis. It has been validated by several
other groups in Romania, Japan and India, with similar results
and cut-offs [133–135]. A recent meta-analysis showed a pooled
AUROC of 0.94, with 94% Se and 95% Sp for advanced ﬁbrosis [5].
Limitations are considerable failure in obtaining measurements
in obese patients [132], however, a new XL probe [136] decreases
the failure rate in obese subjects from 35% to 6% [137]. A caveat
with XL probe is that median measurements were 1.68 kPa lower
as compared to M probe, and therefore different cut-offs will be
needed. Besides obesity, ascites and narrow intercostals spaces
may limit the acquisition of measurements. Several conditions
can falsely increase values of liver stiffness, namely acute hepati-
tis, cholestasis, and hepatic congestion. Regarding the latter, car-
diac failure decompensation, timing of previous hemodialysis in
renal failure and even fasting vs. postprandial state may inﬂuence
the readings. Finally, the technique itself has speciﬁc variability
such as the probe position/inclination and respiratory move-
ments, and the standards described by the manufacturer are
probably not yet optimized.
An alternative to FibroScan is acoustic radiation force
impulse (ARFI) sonoelastography that is based on the principle
of mechanical excitation of tissue by short duration acoustic
pulses. It has the advantage of being integrated in a conventional
US system; therefore it can be performed during standard liver
US [138]. A study in 131 patients with chronic liver disease, ofJournal of Hepatology 2013whom 20 with NAFLD, showed a similar accuracy between Fibro-
Scan and ARFI for ﬁbrosis [139]. Studies on NAFLD are still pre-
liminary with few patients recruited [140,141].
Real-time elastography is a new method that uses a B-mode
US machine, incorporating elastography into the conventional
US scanner. Relative hardness of the tissue is calculated and dis-
played as real-time color images, presented simultaneously as
the B-mode images. It was evaluated in 181 NAFLD patients,
and using hepatic and splenic elastic ratios, diagnostic accuracy
for ﬁbrosis was 82.6–96.0% in all stages [142].
MR elastography allows evaluation throughout the whole
liver. A preliminary study on 50 patients with chronic liver dis-
ease, 20% of whomwith NAFLD, found that a 2.93 kPa cut-off pre-
sented 98% Se and 99% Sp for diagnosing ﬁbrosis [143]. It also
showed good accuracy in differentiating mild from moderate/
severe ﬁbrosis. Another small study, on chronic liver disease, of
which 8% NASH, suggested MR elastography to be superior to
FibroScan concerning success rate and diagnostic/staging accu-
racy [144]. Its major limitations are the costs, small populations
studied and not being broadly available [5].
Summing up for ﬁbrosis, the multitude of scores may lead to
tremendous confusion in what to use in clinical practice. For the
time being, NAFLD Fibrosis Score is the most validated. Also, it
relies on simple parameters, being a good tool for selecting
patients for LB. Elastography techniques seem very accurate,
and are gaining a place in selecting a minority of patients that
really need LB, while avoiding it in a large number of patients,
as it already happens in chronic hepatitis C.vol. 58 j 1007–1019 1015
ReviewKey Points
• In the clinical setting, active search for hepatic 
steatosis in asymptomatic individuals is not 
recommended, except in very precise situations, such
as living donors for liver transplantation. Methods for
screening hepatic steatosis are then more appropriate
in the context of epidemiological studies
• FLI score has been extensively used in epidemiological
studies, as an attempt to avoid US, however, its 
accuracy is not perfect, and it was designed having US
and not LB as gold standard. MRS has demonstrated
an excellent accuracy for detecting and quantifying
steatosis and may even perform better than LB. 
However, it is expensive and not widely available,
CAP seems promising in assessing and quantifying
steatosis, but should be further validated
• Concerning the prediction of NASH, most biomarkers
and complex scores showed suboptimal AUROC.
CK18 fragments, a marker of apoptosis, is the only
biomarker extensively validated. However, it is not
broadly available and as such it has not yet been
introduced in clinical practice
• Regarding fibrosis prediction, the only model 
adequately validated is NAFLD Fibrosis Score that
correctly identifies and excludes advanced fibrosis
in most patients and can avoid LB in a substantial
number of patients. Elastography, either by FibroScan®
or by ARFI, can reliably predict advanced fibrosis and
may help in the decision to perform LB. ARFI has
been less studied, but has the advantage of being
incorporated in a regular US setConclusions
The search for the ideal non-invasive test has not been accom-
plished yet, which explains the vast number of tests available.
Imaging techniques, biomarkers and complex models have been
studied as tools to predict steatosis, NASH and ﬁbrosis. New
methods are usually compared with LB that has accuracy far
from perfect for NASH and even for ﬁbrosis. For assessing stea-
tosis, US may also be used as comparison, and US cannot detect
mild steatosis. In that way, new methods can perform better
than the gold standard leading to underestimation of the power
of the test.
Most methods have been evaluated in small pilot studies and
have not been externally validated. The majority showed only
suboptimal accuracy for NASH. Although discrimination for
advanced ﬁbrosis is usually reasonable, no test detects conﬁ-
dently mild/moderate ﬁbrosis. Also, standardization of cut-offs
is difﬁcult and most methods lack reproducibility.
For the time being, non-invasive tests do not replace LB, but
may avoid it in a large number of cases with low probability or
high-risk for having advanced ﬁbrosis/cirrhosis. A suggestion of
a decision algorithm of when to perform LB, according to current
guidelines and a meta-analysis on non-invasive tools [5,14,145],
is presented in Fig. 1.1016 Journal of Hepatology 2013Conﬂict of interest
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